Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Successful desensitization to brentuximab vedotin after anaphylaxis.

O'Connell AE, Lee JP, Yee C, Kesselheim J, Dioun A.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e73-5. doi: 10.1016/j.clml.2013.11.003. Epub 2013 Nov 15. No abstract available.

PMID:
24373790
2.

Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.

Arora A, Bhatt VR, Liewer S, Armitage JO, Bociek RG.

Eur J Haematol. 2015 Oct;95(4):361-4. doi: 10.1111/ejh.12570. Epub 2015 May 6. Review.

PMID:
25892213
3.

Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.

DeVita MD, Evens AM, Rosen ST, Greenberger PA, Petrich AM.

J Natl Compr Canc Netw. 2014 Apr;12(4):465-71. Review.

PMID:
24717566
4.

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, Advani R.

Leuk Lymphoma. 2015 Mar;56(3):703-10. doi: 10.3109/10428194.2014.930852. Epub 2015 Jan 21.

PMID:
24913507
5.

Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.

Koh KN, Im HJ, Suh JK, Lee SW, Choi ES, Seo JJ.

Pediatr Blood Cancer. 2015 Jun;62(6):1063-5. doi: 10.1002/pbc.25351. Epub 2015 Jan 16.

PMID:
25641881
6.

Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.

Monjanel H, Deville L, Ram-Wolff C, Venon MD, Franchi P, Benet C, de Kerviler E, Malphettes M, Thieblemont C, Brice P.

Br J Haematol. 2014 Jul;166(2):306-8. doi: 10.1111/bjh.12849. Epub 2014 Mar 27. No abstract available.

PMID:
24673542
7.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, Yokoyama M, Takubo T, Kagehara H, Matsushima T.

Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.

8.

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.

Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Review. French.

PMID:
23831822
9.

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.

Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J.

Haematologica. 2013 Apr;98(4):611-4. doi: 10.3324/haematol.2012.069393. Epub 2012 Oct 12.

10.

Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.

Broccoli A, Derenzini E, Pellegrini C, Narducci R, Stefani G, Casadei B, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):493-5. doi: 10.1016/j.clml.2013.03.008. Epub 2013 May 29. No abstract available.

PMID:
23726017
11.

Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.

Foyil KV, Bartlett NL.

Cancer J. 2012 Sep-Oct;18(5):450-6. Review.

PMID:
23006951
12.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.

J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.

PMID:
22614995
13.

Brentuximab vedotin in anaplastic large cell lymphoma.

Skarbnik AP, Smith MR.

Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27.

PMID:
22449148
14.

Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.

Alig SK, Dreyling M, Seppi B, Aulinger B, Witkowski L, Rieger CT.

Eur J Haematol. 2015 Jun;94(6):554-7. doi: 10.1111/ejh.12396. Epub 2014 Jul 2. Review.

PMID:
24913471
15.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
16.

Brentuximab vedotin.

Ansell SM.

Blood. 2014 Nov 20;124(22):3197-200. doi: 10.1182/blood-2014-06-537514. Epub 2014 Oct 7.

17.

FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.

[No authors listed]

Oncology (Williston Park). 2011 Sep;25(10):904. No abstract available.

18.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
19.

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R.

Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.

20.

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Minich SS.

Ann Pharmacother. 2012 Mar;46(3):377-83. doi: 10.1345/aph.1Q680. Epub 2012 Mar 6. Review.

PMID:
22395252

Supplemental Content

Support Center